BACKGROUND: β-Blocker therapy and β-adrenergic receptor (β-AR) polymorphisms are associated with increases in glucose and lipid levels. We investigated associations of common β1 and β2-AR single-nucleotide polymorphisms (SNPs) with metabolic and lipid variables, and examined interactions with β-blocker treatment assignment to affect these parameters. METHODS: This was a post hoc analysis of a double-blinded clinical trial of nondiabetic, hypertensive individuals that were randomized to receive carvedilol or metoprolol succinate. Fastingglucose, insulin, and lipid levels were measured at baseline, 3 months, and after 6 months. Genotypes for β1-ARSNPs Ser49Gly &; Gly389Arg and β2-AR Arg16Gly & Gln27Glu were determined. Multivariable mixed models were used to examine associations between β-AR polymorphisms, metabolic parameters, and SNP interactions with β-blocker therapy (p(interaction)). RESULTS: The 322 subjects were mean (s.d.) 51.5 (11.2) years old. After 6 months, insulin levels increased by 35.6% on metoprolol and 9.9% on carvedilol (P = 0.015). In univariate models, the Gln27Gln genotype had higher overall insulin levels with β-blockade compared to the Glu27Glu genotype (P = 0.006). Both Arg16Gly (P = 0.012) and Gln27Glu (P = 0.037) SNPs were associated with higher triglycerides levels. An interaction between the Arg16Gly SNP and treatment was identified (p(int) = 0.048). CONCLUSIONS: These data suggest that insulin and triglycerides may be influenced by β2-AR polymorphisms in patients taking β blockers.
RCT Entities:
BACKGROUND: β-Blocker therapy and β-adrenergic receptor (β-AR) polymorphisms are associated with increases in glucose and lipid levels. We investigated associations of common β1 and β2-AR single-nucleotide polymorphisms (SNPs) with metabolic and lipid variables, and examined interactions with β-blocker treatment assignment to affect these parameters. METHODS: This was a post hoc analysis of a double-blinded clinical trial of nondiabetic, hypertensive individuals that were randomized to receive carvedilol or metoprolol succinate. Fasting glucose, insulin, and lipid levels were measured at baseline, 3 months, and after 6 months. Genotypes for β1-AR SNPs Ser49Gly & Gly389Arg and β2-AR Arg16Gly & Gln27Glu were determined. Multivariable mixed models were used to examine associations between β-AR polymorphisms, metabolic parameters, and SNP interactions with β-blocker therapy (p(interaction)). RESULTS: The 322 subjects were mean (s.d.) 51.5 (11.2) years old. After 6 months, insulin levels increased by 35.6% on metoprolol and 9.9% on carvedilol (P = 0.015). In univariate models, the Gln27Gln genotype had higher overall insulin levels with β-blockade compared to the Glu27Glu genotype (P = 0.006). Both Arg16Gly (P = 0.012) and Gln27Glu (P = 0.037) SNPs were associated with higher triglycerides levels. An interaction between the Arg16Gly SNP and treatment was identified (p(int) = 0.048). CONCLUSIONS: These data suggest that insulin and triglycerides may be influenced by β2-AR polymorphisms in patients taking β blockers.
Authors: F Filigheddu; J E Reid; C Troffa; P PinnaParpaglia; G Argiolas; A Testa; M Skolnick; N Glorioso Journal: Pharmacogenomics J Date: 2004 Impact factor: 3.550
Authors: Gregory A Hawkins; Kelan Tantisira; Deborah A Meyers; Elizabeth J Ampleford; Wendy C Moore; Barbara Klanderman; Stephen B Liggett; Stephen P Peters; Scott T Weiss; Eugene R Bleecker Journal: Am J Respir Crit Care Med Date: 2006-08-24 Impact factor: 21.405
Authors: B K Kobilka; R A Dixon; T Frielle; H G Dohlman; M A Bolanowski; I S Sigal; T L Yang-Feng; U Francke; M G Caron; R J Lefkowitz Journal: Proc Natl Acad Sci U S A Date: 1987-01 Impact factor: 11.205
Authors: Christian Torp-Pedersen; Marco Metra; Andrew Charlesworth; Phillip Spark; Mary Ann Lukas; Philip A Poole-Wilson; Karl Swedberg; John G F Cleland; Andrea Di Lenarda; Willem J Remme; Armin Scherhag Journal: Heart Date: 2007-01-19 Impact factor: 5.994
Authors: J L González Sánchez; A M Proenza; M T Martínez Larrad; J M Ramis; C Fernández Pérez; A Palou; M Serrano Ríos Journal: Clin Endocrinol (Oxf) Date: 2003-10 Impact factor: 3.478
Authors: Franz H Messerli; David S H Bell; Vivian Fonseca; Richard E Katholi; Janet B McGill; Robert A Phillips; Philip Raskin; Jackson T Wright; Sripal Bangalore; Fred K Holdbrook; Mary Ann Lukas; Karen M Anderson; George L Bakris Journal: Am J Med Date: 2007-07 Impact factor: 4.965
Authors: Weiwei Zeng; Tanya T W Chu; Chung Shun Ho; Clara W S Lo; Alan S L Chan; Alice P S Kong; Brian Tomlinson; Sze Wa Chan Journal: Front Cardiovasc Med Date: 2022-04-01
Authors: Maha H Daghestani; Maha Omair; Mazin Daghestani; Sonya S Abdel-Razeq; Namik Kaya; Arjumand Warsy Journal: J Med Biochem Date: 2021-01-26 Impact factor: 3.402